Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 474
Filter
1.
Pediatr Int ; 66(1): e15722, 2024.
Article in English | MEDLINE | ID: mdl-38299706

ABSTRACT

BACKGROUND: The urine protein to creatinine ratio (UPCR) correlates well with the 24-h urine protein test (24-h UPT) and is a reliable indicator of proteinuria. However, in nephrotic syndrome, the correlation between the UPCR and the 24-h UPT tends to decrease. To address this, we introduced the fractional excretion of total protein (FETP), which reflects serum total protein and creatinine levels because severe hypoproteinemia and/or elevated serum creatinine levels tend to occur under these conditions. The 24-h UPT corrected for body surface area (BSA) (24-h UPT/BSA) was used to take body size into consideration. The correlation coefficients for 24-h UPT/BSA and FETP and 24-h UPT/BSA and UPCR were calculated. The statistical significance of the differences between these coefficients was also calculated. METHODS: Thirty-six pediatric patients with nephrotic syndrome were included in this study. The FETP was calculated as total protein clearance/creatinine clearance (%). Correlation coefficients were calculated for 24-h UPT/BSA and FETP and 24-h UPT/BSA and UPCR. The statistical significance of the differences between these coefficients was also calculated. RESULTS: The mean ± standard error of FETP was 0.11% ± 0.013%. The correlation coefficients of FETP and UPCR with 24-h UPT/BSA were 0.91 and 0.81, respectively. The FETP demonstrated a significantly stronger correlation with 24-h UPT/BSA than with UPCR (p = 0.01). CONCLUSIONS: The FETP correlated more strongly with 24-h UPT/BSA than with UPCR in patients with nephrotic syndrome. The FETP is a reliable indicator of proteinuria in nephrotic syndrome, especially in patients with severe hypoproteinemia or elevated serum creatinine levels.


Subject(s)
Hypoproteinemia , Nephrotic Syndrome , Humans , Child , Nephrotic Syndrome/diagnosis , Nephrotic Syndrome/urine , Creatinine/urine , Proteinuria/diagnosis , Proteinuria/urine , Urinalysis
2.
J Oral Rehabil ; 2024 Jun 08.
Article in English | MEDLINE | ID: mdl-38850071

ABSTRACT

BACKGROUND: Prevotella bacteria are associated with inherent diseases of the oral cavity, such as periodontal disease, and systemic diseases. Oral frailty (OF) has been associated with nursing necessity and death. However, the relationship between OF and oral microbiota has not been fully clarified. OBJECTIVE: This cross-sectional study investigated the association between OF and Prevotella percentage in the oral microbiota of community-dwelling older adults. METHODS: Oral bacteria species from saliva were identified in 208 community-dwelling older individuals aged ≥60 years in Japan. The proportion of Prevotella in the oral microbiota was classified into three tertile groups, and its relationship with each test item for OF (number of remaining teeth, masticatory performance, oral diadochokinesis, tongue pressure, difficulties eating tough foods, difficulties swallowing tea or soup, number of applicable OF judgement items, and existence of OF) was examined using ordinal logistic regression analysis. RESULTS: The Prevotella proportions were classified into lower, middle and upper groups, comprising 70, 69 and 69 participants, respectively. The three groups showed a significant relationship between the number of remaining teeth (odds ratio [OR]: 0.946, 95% confidence interval [CI]: 0.915-0.977), masticatory performance (OR: 0.897, 95% CI: 0.844-0.953), number of applicable OF judgement items (OR: 1.477, 95% CI: 1.14-1.915), and existence of OF (OR: 4.194, 95% CI: 1.519-11.576). CONCLUSION: The proportion of Prevotella in oral microbiota was high in individuals with OF. Among the older adults, the type of oral microbiota and systemic diseases may be related to the examination and management of oral function decline.

3.
Article in Japanese | MEDLINE | ID: mdl-38910126

ABSTRACT

Objective To decrease cancer mortality by implementing cancer screening programs, rigorous quality control measures that utilize standardized indicators are imperative. In Japan, although each municipality performing cancer screening programs implements quality control for their programs using the checklist authorized by the Ministry of Health, Labour and Welfare, compliance with all the items listed is not possible because calculating sensitivity and specificity using cancer registry data is difficult under these circumstances. This report elucidates the methodology for calculating indicators, including sensitivity and specificity, by delineating the parameters of false-negative cases within population-based cancer screening programs in Japan. Furthermore, the inherent challenges associated with ensuring the quality control of cancer screening procedures are expounded upon in this report.Method Data from the Prefectural Cancer Registry of Japan and cancer screening records compiled by municipalities were used to differentiate true-positive, true-negative, false-positive, and false-negative cases based on the combination of screening test outcomes and subsequent cancer incidence.Results A false-negative case was defined as an examinee who received a cancer diagnosis within one year after undergoing the screening test, notwithstanding the negative judgment of the cancer screening decision. The duration for judgment of true-positive, true-negative, and false-negative cases was also extended to one year. Cancer identification after cancer screening was ascertained using data from the Prefectural Cancer Registry, ensuring uniform categorization of the four cases. Subsequently, sensitivity and specificity values were calculated for municipalities conducting cancer screening programs.Conclusion Sensitivity and specificity are indispensable metrics for the inherent quality control of cancer screening because these parameters directly assess the efficacy of screening tests. The anticipated increase in the number of municipalities engaged in comprehensive quality control of cancer screening in Japan is poised to enhance the efficiency of cancer control policies. This augmentation will be accomplished through the meticulous utilization of the sensitivity and specificity values elucidated in the present report. The forthcoming challenges involve the proliferation of medical institutes reporting their adherence to the checklist stipulated by the National Cancer Center of Japan and the widespread dissemination of fundamental knowledge pertaining to cancer screening.

4.
Gut ; 72(10): 1904-1918, 2023 10.
Article in English | MEDLINE | ID: mdl-37463757

ABSTRACT

OBJECTIVE: New screening tests for colorectal cancer (CRC) are rapidly emerging. Conducting trials with mortality reduction as the end point supporting their adoption is challenging. We re-examined the principles underlying evaluation of new non-invasive tests in view of technological developments and identification of new biomarkers. DESIGN: A formal consensus approach involving a multidisciplinary expert panel revised eight previously established principles. RESULTS: Twelve newly stated principles emerged. Effectiveness of a new test can be evaluated by comparison with a proven comparator non-invasive test. The faecal immunochemical test is now considered the appropriate comparator, while colonoscopy remains the diagnostic standard. For a new test to be able to meet differing screening goals and regulatory requirements, flexibility to adjust its positivity threshold is desirable. A rigorous and efficient four-phased approach is proposed, commencing with small studies assessing the test's ability to discriminate between CRC and non-cancer states (phase I), followed by prospective estimation of accuracy across the continuum of neoplastic lesions in neoplasia-enriched populations (phase II). If these show promise, a provisional test positivity threshold is set before evaluation in typical screening populations. Phase III prospective studies determine single round intention-to-screen programme outcomes and confirm the test positivity threshold. Phase IV studies involve evaluation over repeated screening rounds with monitoring for missed lesions. Phases III and IV findings will provide the real-world data required to model test impact on CRC mortality and incidence. CONCLUSION: New non-invasive tests can be efficiently evaluated by a rigorous phased comparative approach, generating data from unbiased populations that inform predictions of their health impact.


Subject(s)
Colorectal Neoplasms , Mass Screening , Humans , Prospective Studies , Early Detection of Cancer , Colorectal Neoplasms/epidemiology , Colonoscopy , Occult Blood , Feces
5.
J Am Chem Soc ; 145(48): 25976-25982, 2023 Dec 06.
Article in English | MEDLINE | ID: mdl-37983189

ABSTRACT

The base strength of oxide catalysts is controlled by the electron charge distribution between cations and anions, with unsaturated oxygen ions that have lone pair electrons typically acting as basic sites. Substitution of oxide ions with anions that have different valences, such as nitride and hydride ions, can often generate basic sites. It is plausible that electrons trapped at oxygen vacancy sites could provide increased electron density and shift the highest occupied molecular orbital energy levels of anions upward in the case that the oxygen vacancies couple with surface-substituted anions. The present work demonstrates that high catalytic basicity can be obtained via site-selective doping of anions at face-sharing Ti2O9 dimer sites with oxygen vacancies in BaTiO3-x. This improved basicity stems from the coupling of substituted nitride ions to electrons at oxygen vacancies. The oxynitride BaTiO3-xNy was found to contain nitride ions that have increased electronic charge density on the basis of such interactions. Enhanced surface basicity following doping with nitride ion was also confirmed by CO2 temperature-programmed desorption and infrared spectroscopy in conjunction with the adsorption of CHCl3. The strong Lewis base sites resulting from the formation of the oxynitride evidently facilitated the catalytic activation of C-H bonds to promote Knoevenagel condensation reactions between aldehydes and active methylene compounds with pKa values of up to 28.9.

6.
BMC Pulm Med ; 23(1): 312, 2023 Aug 28.
Article in English | MEDLINE | ID: mdl-37641057

ABSTRACT

BACKGROUND: During the fifth wave of the coronavirus disease 2019 (COVID-19) pandemic in Japan, which took place between June and September 2021, a significant number of COVID-19 cases with deterioration occurred in unvaccinated individuals < 65 years old. However, the risk factors for COVID-19 deterioration in this specific population have not yet been determined. This study developed a prediction method to identify COVID-19 patients < 65 years old who are at a high risk of deterioration. METHODS: This retrospective study analyzed data from 1,675 patients < 65 years old who were admitted to acute care institutions in Fukushima with mild-to-moderate-1 COVID-19 based on the Japanese disease severity criteria prior to the fifth wave. For validation, 324 similar patients were enrolled from 3 hospitals in Yamagata. Logistic regression analyses using cluster-robust variance estimation were used to determine predictors of disease deterioration, followed by creation of risk prediction scores. Disease deterioration was defined as the initiation of medication for COVID-19, oxygen inhalation, or mechanical ventilation starting one day or later after admission. RESULTS: The patients whose condition deteriorated (8.6%) tended to be older, male, have histories of smoking, and have high body temperatures, low oxygen saturation values, and comorbidities, such as diabetes/obesity and hypertension. Stepwise variable selection using logistic regression to predict COVID-19 deterioration retained comorbidities of diabetes/obesity (DO), age (A), body temperature (T), and oxygen saturation (S). Two predictive scores were created based on the optimism-corrected regression coefficients: the DOATS score, including all of the above risk factors, and the DOAT score, which was the DOATS score without oxygen saturation. In the original cohort, the areas under the receiver operating characteristic curve (AUROCs) of the DOATS and DOAT scores were 0.81 (95% confidence interval [CI] 0.77-0.85) and 0.80 (95% CI 0.76-0.84), respectively. In the validation cohort, the AUROCs for each score were both 0.76 (95% CI 0.69-0.83), and the calibration slopes were both 0.80. A decision curve analysis confirmed the clinical practicability of both scores in the validation cohort. CONCLUSIONS: We established two prediction scores that can quickly evaluate the risk of COVID-19 deterioration in mild/moderate patients < 65 years old.


Subject(s)
COVID-19 , Diabetes Mellitus , Humans , Male , Aged , COVID-19/epidemiology , Retrospective Studies , Disease Progression , Diabetes Mellitus/epidemiology , Obesity/epidemiology
7.
J Cell Physiol ; 237(1): 706-719, 2022 01.
Article in English | MEDLINE | ID: mdl-34369600

ABSTRACT

Elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) are documented in patients with sepsis and levels positively correlate with disease severity and mortality. Our previous work demonstrated that visceral adipose tissues (VAT) are a major source of PAI-1, especially in the aged (murine endotoxemia), that circulating PAI-1 protein levels match the trajectory of PAI-1 transcript levels in VAT (clinical sepsis), and that PAI-1 in both VAT and plasma are positively associated with acute kidney injury (AKI) in septic patients. In the current study utilizing preclinical sepsis models, PAI-1 tissue distribution was examined and cellular sources, as well as mechanisms mediating PAI-1 induction in VAT, were identified. In aged mice with sepsis, PAI-1 gene expression was significantly higher in VAT than in other major organs. VAT PAI-1 gene expression correlated with PAI-1 protein levels in both VAT and plasma. Moreover, VAT and plasma levels of PAI-1 were positively associated with AKI markers, modeling our previous clinical data. Using explant cultures of VAT, we determined that PAI-1 is secreted robustly in response to recombinant transforming growth factor ß (TGFß) and tumor necrosis factor α (TNFα) treatment; however, neutralization was effective only for TNFα indicating that TGFß is not an endogenous modulator of PAI-1. Within VAT, TNFα was localized to neutrophils and macrophages. PAI-1 protein levels were fourfold higher in stromal vascular fraction (SVF) cells compared with mature adipocytes, and among SVF cells, both immune and nonimmune compartments expressed PAI-1 in a similar fashion. PAI-1 was localized predominantly to macrophages within the immune compartment and preadipocytes and endothelial cells within the nonimmune compartment. Collectively, these results indicate that induction and secretion of PAI-1 from VAT is facilitated by a complex interaction among immune and nonimmune cells. As circulating PAI-1 contributes to AKI in sepsis, understanding PAI-1 regulation in VAT could yield novel strategies for reducing systemic consequences of PAI-1 overproduction.


Subject(s)
Acute Kidney Injury , Sepsis , Animals , Endothelial Cells/metabolism , Intra-Abdominal Fat/metabolism , Mice , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/metabolism , Transforming Growth Factor beta , Tumor Necrosis Factor-alpha/pharmacology
8.
Nutr Metab Cardiovasc Dis ; 32(2): 365-372, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34893406

ABSTRACT

BACKGROUND AND AIMS: Frailty and sarcopenia are common and confer poor prognosis in elderly patients with heart failure; however, gender differences in its prevalence or prognostic impact remain unclear. METHODS AND RESULTS: We included 1332 patients aged ≥65 years, who were hospitalized for heart failure. Frailty and sarcopenia were defined using the Fried phenotype model and Asian Working Group for Sarcopenia criteria, respectively. Gender differences in frailty and sarcopenia, and interactions between sex and prognostic impact of frailty/sarcopenia on 1-year mortality were evaluated. Overall, 53.9% men and 61.0% women and 23.7% men and 14.0% women had frailty and sarcopenia, respectively. Although sarcopenia was more prevalent in men, no gender differences existed in frailty after adjusting for age. On Kaplan-Meier analysis, frailty and sarcopenia were significantly associated with 1-year mortality in both sexes. On Cox proportional hazard analysis, frailty was associated with 1-year mortality only in men, after adjusting for confounding factors (hazard ratio [HR], 1.94; 95% confidence interval [CI], 1.19-3.16; P = 0.008 for men; HR, 1.63; 95% CI, 0.84-3.13; P = 0.147 for women); sarcopenia was an independent prognostic factor in both sexes (HR, 1.93; 95% CI, 1.13-3.31; P = 0.017 for men; HR, 3.18; 95% CI, 1.59-5.64; P = 0.001 for women). There were no interactions between sex and prognostic impact of frailty/sarcopenia (P = 0.806 for frailty; P = 0.254 for sarcopenia). CONCLUSIONS: Frailty and sarcopenia negatively affect older patients with heart failure from both sexes. CLINICAL TRIALS: This study was registered at the University Hospital Information Network (UMIN-CTR, unique identifier: UMIN000023929) before the first patient was enrolled.


Subject(s)
Frailty , Heart Failure , Sarcopenia , Aged , Female , Frail Elderly , Frailty/diagnosis , Frailty/epidemiology , Heart Failure/complications , Heart Failure/diagnosis , Heart Failure/epidemiology , Humans , Male , Prevalence , Prognosis , Sarcopenia/complications , Sarcopenia/diagnosis , Sarcopenia/epidemiology , Sex Characteristics , Sex Factors
9.
BMC Geriatr ; 22(1): 556, 2022 07 05.
Article in English | MEDLINE | ID: mdl-35787667

ABSTRACT

BACKGROUND: The purpose of this study was to clarify the prevalence, association with frailty and exercise capacity, and prognostic implication of sarcopenic obesity in patients with heart failure. METHODS: The present study included 779 older adults hospitalized with heart failure (median age: 81 years; 57.4% men). Sarcopenia was diagnosed based on the guidelines by the Asian Working Group for Sarcopenia. Obesity was defined as the percentage of body fat mass (FM) obtained by bioelectrical impedance analysis. The FM cut-off points for obesity were 38% for women and 27% for men. The primary endpoint was 1-year all-cause death. We assessed the associations of sarcopenic obesity occurrence with the short physical performance battery (SPPB) score and 6-minute walk distance (6MWD). RESULTS: The rates of sarcopenia and obesity were 19.3 and 26.2%, respectively. The patients were classified into the following groups: non-sarcopenia/non-obesity (58.5%), non-sarcopenia/obesity (22.2%), sarcopenia/non-obesity (15.3%), and sarcopenia/obesity (4.0%). The sarcopenia/obesity group had a lower SPPB score and shorter 6MWD, which was independent of age and sex (coefficient, - 0.120; t-value, - 3.74; P < 0.001 and coefficient, - 77.42; t-value, - 3.61; P < 0.001; respectively). Ninety-six patients died during the 1-year follow-up period. In a Cox proportional hazard analysis, sarcopenia and obesity together were an independent prognostic factor even after adjusting for a coexisting prognostic factor (non-sarcopenia/non-obesity vs. sarcopenia/obesity: hazard ratio, 2.48; 95% confidence interval, 1.22-5.04; P = 0.012). CONCLUSION: Sarcopenic obesity is a risk factor for all-cause death and low physical function in older adults with heart failure. TRIAL REGISTRATION: University Hospital Information Network (UMIN-CTR: UMIN000023929 ).


Subject(s)
Heart Failure , Sarcopenia , Aged , Aged, 80 and over , Female , Heart Failure/complications , Heart Failure/diagnosis , Heart Failure/epidemiology , Humans , Male , Obesity/complications , Obesity/diagnosis , Obesity/epidemiology , Prevalence , Risk Factors , Sarcopenia/diagnosis , Sarcopenia/epidemiology
10.
Gerodontology ; 39(1): 49-58, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35098575

ABSTRACT

OBJECTIVE: To examine the association between oral frailty and oral Candida carriage as a general indicator of deteriorating oral function in older adults. BACKGROUND: Older adults exhibit an elevated risk of oral candidiasis caused by Candida. Although many studies have identified factors associated with oral Candida carriage, none have evaluated its relationship with oral function. MATERIALS AND METHODS: This study included 210 community-dwelling older adults aged ≥60 years who participated in wellness checks. Fungal flora expression in saliva samples was evaluated to identify oral C. albicans and C. glabrata. Participants were categorised by detection of neither strain (group 1), either one of the strains (group 2), or both strains (group 3). The relationship between oral Candida carriage and oral frailty was evaluated by multinomial logistic regression analysis. RESULTS: The participants included 58 men and 152 women with a mean age of 74.2 ± 6.1 years. A total of 88 (41.9%), 94 (44.8%) and 28 (13.3%) participants were assigned to groups 1, 2 and 3 respectively. In the multinomial logistic regression analysis, significant associations were observed between group 1 and group 2 for "Have you choked on your tea or soup recently?" and the number of applicable oral frailty items. Between group 1 and group 3, significant associations were observed for the number of remaining teeth, masticatory performance and the number of applicable oral frailty items. CONCLUSION: We obtained basic data useful for intervention studies aimed at verifying whether oral function management prevents deterioration of the oral bacterial flora.


Subject(s)
Frailty , Aged , Aged, 80 and over , Candida , Cross-Sectional Studies , Female , Frail Elderly , Humans , Independent Living , Male , Oral Health
11.
Curr Heart Fail Rep ; 18(3): 107-120, 2021 06.
Article in English | MEDLINE | ID: mdl-33835397

ABSTRACT

PURPOSE OF REVIEW: With a worldwide aging population, frailty and heart failure (HF) have become issues that need to be addressed urgently in cardiovascular clinical practice. In this review, we outline the clinical implications of frailty in HF patients and the potential therapeutic strategies to improve the clinical outcomes of frail patients with HF. RECENT FINDINGS: Frailty has physical, psychological, and social domains, each of which is a prognostic determinant for patients with HF, and each domain overlaps with the other, although there are no standardized criteria for diagnosing frailty. Frailty can be targeted for treatment with various interventions, and recent studies have suggested that multidisciplinary intervention could be a promising option for frail patients with HF. However, currently, there is limited data, and further research is needed before its clinical implementation. Frailty and HF share a common background and are strongly associated with each other. More comprehensive assessment and therapeutic interventions for frailty need to be developed to further improve the prognosis and quality of life of frail patients with HF.


Subject(s)
Frailty , Heart Failure , Aged , Aging , Frail Elderly , Frailty/epidemiology , Heart Failure/epidemiology , Heart Failure/therapy , Humans , Quality of Life
12.
J Strength Cond Res ; 35(5): 1389-1396, 2021 May 01.
Article in English | MEDLINE | ID: mdl-30694970

ABSTRACT

ABSTRACT: Matsumoto M, Satoh, K, Kushi, H, Hamuro, K, Sakurai, M, Saito, H, Tanaka, R, Saito, T, Kohda, N, and Hamada, K. Salivary immunoglobulin A secretion rate during peak period conditioning regimens in triathletes. J Strength Cond Res 35(5): 1389-1396, 2021-Triathletes often feel unwell during the conditioning period (peak period) leading up to a race. The aim of this study was to evaluate the factors relevant to the condition of athletes and their impact on mucosal immune responses and the salivary immunoglobulin A (IgA) secretion rate. This study recruited college student triathletes (33 men and 7 women) who participated in an Olympic distance race. For each subject, the salivary IgA rate was measured continuously for 1 month before the race (peak period). Data on physical activity during the peak period were calculated in metabolic equivalents, and the relationships between these factors and the salivary IgA secretion rate were evaluated. The average amount of physical activity was highest during the 2- to 3-week period before the race, at 744.7 ± 51.5 kcal expended per day. In subjects who, on average, expended more than 1,000 kcal·d-1 in physical activity between 12 and 14 days before the race, the salivary IgA secretion rate was significantly reduced compared with the value at 1 week before the race (p < 0.05). On the day before the race, a further reduction was observed (p < 0.1). The salivary IgA secretion rate was decreased by high-intensity exercise during the peak period in advance of a race; this was associated with a loss of optimal condition just before the race.


Subject(s)
Immunoglobulin A, Secretory , Saliva , Sports , Athletes , Exercise , Female , Humans , Male
13.
Int J Colorectal Dis ; 35(5): 933-939, 2020 May.
Article in English | MEDLINE | ID: mdl-32034490

ABSTRACT

PURPOSE: Screening programs using fecal occult blood testing help reduce mortality from colorectal cancer (CRC). Colonoscopy and colonoscopy combined with fecal occult blood testing are considered alternatives with higher sensitivity than fecal tests; however, to our knowledge, randomized controlled trials (RCTs) providing such evidence have not been reported. Therefore, this study aimed to compare screening using the fecal immunochemical test (FIT) combined with colonoscopy and FIT alone to evaluate the efficacy of colonoscopy screening in reducing CRC mortality. METHODS: This multicenter, prospective, randomized, controlled study included average-risk individuals for CRC living in the study areas and aged 40-74 years. The exclusion criteria were history of CRC, hereditary non-polyposis CRC, familial adenomatous polyposis, inflammatory bowel diseases, history of cancer other than CRC within the past 5 years, and not expected to survive from comorbid illness. The intervention group underwent one-time colonoscopy and annual FIT, while the control group underwent annual FIT. The primary endpoint was mortality from CRC, while the secondary endpoints were cumulative incidence of invasive CRC, advanced CRC (invasion into the muscle layer or deeper), invasive cancer and screening sensitivities and specificities of invasive CRC, whole CRC, advanced neoplasia, and prevalence of adverse events. The intervention and control groups comprised 4876 and 4875 participants, respectively. CONCLUSION: This explanatory RCT evaluated the efficacy of colonoscopy screening by valid statistical inference based on randomization. Data on adverse events from this kind of screening are necessary when considering implementation of future screening programs. TRIAL REGISTRATION: UMIN Clinical Trials Registry, number UMIN000001980.


Subject(s)
Colonoscopy , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/mortality , Early Detection of Cancer , Feces , Immunohistochemistry , Adult , Aged , Female , Humans , Japan , Male , Middle Aged , Sample Size , Statistics as Topic
16.
No Shinkei Geka ; 48(5): 407-412, 2020 May.
Article in Japanese | MEDLINE | ID: mdl-32434951

ABSTRACT

Organized hematoma is a rare, non-neoplastic, and hemorrhage-prone condition that requires attention due to the risk of intraoperative bleeding. Preoperative embolization was performed to ensure intraoperative hemorrhage control. Here, we report a case of preoperative embolization of an organized hematoma using a low-concentration of n-butyl-2-cyanoacrylate(NBCA). An 80-year-old male presented with a 2-month history of repeated nasal bleeding and nasal obstruction. Diagnostic imaging revealed a mass measuring 3.7 cm in the right maxillary sinus with thinning of the surrounding bone. This was diagnosed as an organized hematoma with a biopsy. As a preoperative treatment, embolization of the main feeding artery was performed through the external carotid artery, using a low concentration of NBCA(5%). When the NBCA cast had reached the organized hematoma, as observed on plain CT, endoscopic sinus surgery was performed, and the organized hematoma was resected without significant bleeding. Preoperative embolization of the organized hematoma with low-concentration NBCA was useful to prevent heavy intraoperative bleeding.


Subject(s)
Embolization, Therapeutic , Enbucrilate , Aged, 80 and over , Attention , Hematoma/therapy , Humans , Male , Maxillary Sinus , Treatment Outcome
17.
Gan To Kagaku Ryoho ; 47(5): 843-846, 2020 May.
Article in Japanese | MEDLINE | ID: mdl-32408333

ABSTRACT

A 43-year-old man underwent a low anterior resection of the rectum due to upper rectal cancer. The pathological Stage was Ⅳ with para-aortic lymph node metastasis. Postoperative chemotherapy with CapeOX was initiated, but para-aortic lymph node metastasis was discovered 4months after the surgery. Chemoradiation therapy with Cape and Bev, and 70 Gy/28 Fr led to the disappearance of the metastasized lesions. At 13months after the surgery, FDG accumulation was observed in the Virchow's lymph node, and chemotherapy with IRIS and Bev was initially administered. Subsequently, chemoradiation therapy with S-1 and Bev, and 66 Gy/33Fr was administered, followed by chemotherapy with S-1 and Bev, S-1. These therapies led to complete response(CR). However, 35 months after the surgery, the Virchow's lymph node had enlarged again, and chemoradiation therapy with S-1 and 60 Gy/30Fr was administered. Although no FDG accumulation was detected in the lymph node at 40 months after the surgery, metastasis was found in the mediastinal lymph nodes. Panitumumab therapy achieved CR, and no metastasis had been identified at 60 months after the final therapy. Chemoradiation therapy is a treatment option to improve the prognosis of patients with metastasis only in the Virchow's lymph node.


Subject(s)
Rectal Neoplasms , Adult , Antineoplastic Combined Chemotherapy Protocols , Chemoradiotherapy , Humans , Lymph Nodes , Lymphatic Metastasis , Male , Rectal Neoplasms/drug therapy
18.
Oncologist ; 24(7): e583-e589, 2019 07.
Article in English | MEDLINE | ID: mdl-30659079

ABSTRACT

BACKGROUND: Although the efficacy of parenteral morphine for alleviating dyspnea has been previously demonstrated in several studies, little is known regarding the efficacy of oral morphine for dyspnea among patients with cancer, including its response rate and predictive factors of effectiveness. Therefore, the aim of this study was to clarify the effectiveness of oral morphine on dyspnea in patients with cancer and elucidate the predictive factors of its effectiveness. SUBJECTS, MATERIALS, AND METHODS: In this multicenter prospective observational study, we investigated the change in dyspnea intensity in patients with cancer before and after the administration of oral morphine by using a visual analog scale (VAS). We also administered a self-assessment questionnaire to determine whether the patients believed oral morphine was effective. RESULTS: Eighty patients were enrolled in the study, and 71 of these patients were eligible. The least square mean of the VAS scores for dyspnea intensity was 53.5 at baseline, which decreased significantly to 44.7, 40.8, and 35.0 at 30, 60, and 120 minutes after morphine administration, respectively. Fifty-four patients (76.1%) reported that oral morphine was effective on the self-assessment questionnaire. Among the background factors, a high score for "sense of discomfort" on the Cancer Dyspnea Scale (CDS) and a smoking history of fewer pack-years were associated with greater effectiveness. CONCLUSION: Oral morphine was effective and feasible for treating cancer-related dyspnea. A higher score for "sense of discomfort" on the CDS and a smaller cumulative amount of smoking may be predictive factors of the effectiveness of oral morphine. IMPLICATIONS FOR PRACTICE: This study demonstrated that oral morphine was effective in alleviating cancer-related dyspnea due to multiple factors including primary lung lesions, airway narrowing, and pleural effusion. Approximately 76% of patients reported that oral morphine was effective. A higher score for "sense of discomfort" on the Cancer Dyspnea Scale and a lower cumulative amount of smoking may be predictive factors for the effectiveness of oral morphine. Interestingly, respiratory rates in patients who reported the morphine to be effective decreased significantly after oral morphine administration, unlike the respiratory rates in "morphine-ineffective" patients.


Subject(s)
Dyspnea/drug therapy , Morphine/therapeutic use , Administration, Oral , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Morphine/pharmacology , Neoplasms , Prospective Studies , Young Adult
19.
Acta Haematol ; 141(4): 201-208, 2019.
Article in English | MEDLINE | ID: mdl-30943466

ABSTRACT

BACKGROUND/AIMS: Storage iron turnover has remained poorly understood since 1953. In addition, errors in measurements of the storage iron turnover rate (SIT) by ferrokinetics have been detected and the causes of those errors need to be elucidated. METHODS: A new, computer-assisted method, "serum ferritin kinetics," was introduced for the quantitation of ferritin iron and hemosiderin iron. Ferrokinetics and non-ferrokinetic methods were used to determine the body iron turnover rate. RESULTS AND CONCLUSION: Using serum ferritin kinetics, patients with normal iron stores and iron overload were found to have 2 iron pathways between ferritin and hemosiderin: recovery of ferritin taking iron from hemosiderin in iron mobilization and iron transformation from ferritin to hemosiderin in iron deposition. In addition, underestimation of the SIT by ferrokinetics was confirmed by comparing SIT by ferrokinetics with the standard SIT as the sum of SIT of 3 major iron-storing cells. This underestimation was caused by extra radio-iron fixation to red cells. Ferrokinetics does not give the actual body iron turnover due to the behavioral difference between radio-iron and pre-existing body iron. Recent findings on ferritin and hemosiderin iron turnover will be a potential tool for the diagnosis and therapy of hematological disorders.


Subject(s)
Erythrocytes/metabolism , Ferritins/blood , Hematologic Diseases/blood , Hemosiderin/metabolism , Iron Overload/blood , Iron/blood , Animals , Humans
20.
Cancer ; 124(3): 606-616, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29205286

ABSTRACT

BACKGROUND: Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHODS: This double-blind clinical trial (ONO-7643-04) enrolled 174 patients with unresectable stage III/IV non-small cell lung cancer (NSCLC) and cachexia in Japan. Patients were randomized to daily oral anamorelin (100 mg) or a placebo for 12 weeks. The primary endpoint was the change from the baseline LBM (measured with dual-energy x-ray absorptiometry) over 12 weeks. The secondary endpoints were changes in appetite, body weight, quality of life, handgrip strength (HGS), and 6-minute walk test (6MWT) results. RESULTS: The least squares mean change (plus or minus the standard error) in LBM from the baseline over 12 weeks was 1.38 ± 0.18 and -0.17 ± 0.17 kg in the anamorelin and placebo groups, respectively (P < .0001). Changes from the baseline in LBM, body weight, and anorexia symptoms showed significant differences between the 2 treatment groups at all time points. Anamorelin increased prealbumin at weeks 3 and 9. No changes in HGS or 6MWT were detected between the groups. Twelve weeks' treatment with anamorelin was safe and well tolerated in NSCLC patients. CONCLUSIONS: Anamorelin significantly increased LBM and improved anorexia symptoms and the nutritional state, but not motor function, in Japanese patients with advanced NSCLC. Because no effective treatment for cancer cachexia is currently available, anamorelin can be a beneficial treatment option. Cancer 2018;124:606-16. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.


Subject(s)
Cachexia/drug therapy , Carcinoma, Non-Small-Cell Lung/drug therapy , Hydrazines/therapeutic use , Lung Neoplasms/drug therapy , Oligopeptides/therapeutic use , Aged , Body Composition/drug effects , Carcinoma, Non-Small-Cell Lung/metabolism , Double-Blind Method , Female , Humans , Hydrazines/adverse effects , Lung Neoplasms/metabolism , Male , Middle Aged , Oligopeptides/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL